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In subclinical hypothyroidism, the presence of depressive symptoms is often a reason for starting 
levothyroxine treatment. However, data are conflicting on the association between subclinical thyroid 
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dysfunction and depressive symptoms. We aimed to examine the association between subclinical 
thyroid dysfunction and depressive symptoms in all prospective cohorts with relevant data available. 
We performed a systematic review of the literature from Medline, Embase, Cumulative Index to 
Nursing and Allied Health Literature, and the Cochrane Library from inception to 10th May 2019. We 
included prospective cohorts with data on thyroid status at baseline and depressive symptoms during 
follow‑up. The primary outcome was depressive symptoms measured at first available follow‑up, 
expressed on the Beck’s Depression Inventory (BDI) scale (range 0–63, higher values indicate more 
depressive symptoms, minimal clinically important difference: 5 points). We performed a two‑
stage individual participant data (IPD) analysis comparing participants with subclinical hypo‑ or 
hyperthyroidism versus euthyroidism, adjusting for depressive symptoms at baseline, age, sex, 
education, and income (PROSPERO CRD42018091627). Six cohorts met the inclusion criteria, with IPD 
on 23,038 participants. Their mean age was 60 years, 65% were female, 21,025 were euthyroid, 1342 
had subclinical hypothyroidism and 671 subclinical hyperthyroidism. At first available follow‑up [mean 
8.2 (± 4.3) years], BDI scores did not differ between participants with subclinical hypothyroidism (mean 
difference = 0.29, 95% confidence interval =  − 0.17 to 0.76,  I2 = 15.6) or subclinical hyperthyroidism 
(− 0.10, 95% confidence interval =  − 0.67 to 0.48,  I2 = 3.2) compared to euthyroidism. This systematic 
review and IPD analysis of six prospective cohort studies found no clinically relevant association 
between subclinical thyroid dysfunction at baseline and depressive symptoms during follow‑up. 
The results were robust in all sensitivity and subgroup analyses. Our results are in contrast with the 
traditional notion that subclinical thyroid dysfunction, and subclinical hypothyroidism in particular, 
is associated with depressive symptoms. Consequently, our results do not support the practice of 
prescribing levothyroxine in patients with subclinical hypothyroidism to reduce the risk of developing 
depressive symptoms.
Abbreviations
BDI  Beck depression inventory
CESD  Center for epidemiological studies depression
CI  Confidence interval
CINAHL  Cumulative index to nursing and allied health literature
DSM-5  Diagnostic and statistical manual of mental disorders, fifth edition
fT3  Free triiodothyronine
fT4  Free thyroxine
GDS  Geriatric depression scale
HADS  Hospital anxiety and depression scale
ICD  International statistical classification of diseases and related health problems
IPD  Individual participant data/individual patient data
MD  Mean difference
MMSE  Mini-mental state examination
N  Number
NOS  Newcastle–Ottawa scale
PRISMA  Preferred reporting items for systematic reviews and meta-analyses
PROSPERO  International prospective register of systematic reviews
SD  Standard deviation
SHyper  Subclinical hyperthyroidism
SHypo  Subclinical hypothyroidism
SMD  Standardized mean difference
TSH  Thyroid-stimulating hormone
y  Year
Subclinical thyroid dysfunction is common in the adult population and its prevalence increases with age, affect-
ing up to 10–15% of older  adults1. Patients are diagnosed with subclinical thyroid dysfunction when their serum 
thyroid-stimulating hormone (TSH) levels are below or above the reference range, but when their serum free 
thyroxine (fT4) levels are still within the reference range. Only a few symptoms are usually linked to subclini-
cal thyroid dysfunction. Several guidelines discuss the association between depressive symptoms and thyroid 
dysfunction, and the potential benefit of levothyroxine for patients with the two  diagnoses2–5. However, as 
the evidence is low, guidelines do not recommend to routinely treat patients with subclinical hypothyroidism 
and depressive symptoms with levothyroxine. Nevertheless, a study among GPs reported that the presence of 
depressive symptoms or low mood influence their decision whether or not to start treatment for subclinical 
 hypothyroidism6.
The association between subclinical thyroid dysfunction and depressive symptoms is unclear because stud-
ies to date have yielded conflicting results. Several studies showed that participants with subclinical hypothy-
roidism or subclinical hyperthyroidism had more severe depressive symptoms, but other studies reported no 
 differences7–15. The largest prospective study published showed no association between subclinical hypothyroid-
ism and incidence of depression after 2 years of follow-up16, whereas depressive symptoms were associated with 
subclinical hyperthyroidism (but not subclinical hypothyroidism) in another prospective  study11.
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These conflicting results may be explained by differences in outcome definition and in the statistical methods 
used to analyse data. Individual participant data (IPD) help researchers to standardise the analyses and definitions 
used across studies and make it possible to identify the effects for different subgroups in large study  populations17. 
For example, IPD allow the use of uniform cut-off levels of TSH to define thyroid status for each study, the same 
model for the analysis in each study, and stratification by age and sex.
We thus aimed to assess the association between subclinical hypothyroidism or subclinical hyperthyroid-
ism and future development of depressive symptoms by conducting an analysis of IPD from prospective cohort 
studies.
Methods
We registered this systematic review and IPD analysis in the international Prospective Register of Systematic 
Reviews PROSPERO (CRD42018091627) and published the study  protocol18. This study adheres to the Preferred 
Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement for IPD systematic  reviews19.
Search strategy and selection criteria. We performed a systematic literature search in Ovid Medline, 
Ovid Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and in the Cochrane 
Library, from inception to 10th May 2019. We included publications from prospective studies that measured 
at least baseline TSH in adults and assessed depressive symptoms during follow-up on a validated continuous 
depression scale or diagnosis of depression (e.g. through ICD-10 or DSM-V codes). The following search items 
were used: thyroid diseases, hyperthyroidism, hypothyroidism, thyroid hormones, triiodothyronine, thyroxine, 
thyrotropin, subclinical, sub-clinical, mild, subnormal, pre-clinical, preclinical, depression. We did not include 
studies of only depressed patients, pregnant women, or women wanting to get pregnant. We included studies in 
any language and any publication year. We worked with two experienced librarians to develop the search strat-
egy in Ovid Medline and then translated it to match subject headings and keywords for the other databases. See 
Appendix 1 for details of the Medline search strategy. Details of the systematic literature search, inclusion and 
exclusion criteria, and IPD analysis have been described in detail  elsewhere18. We identified additional unpub-
lished data by contacting the Thyroid Studies Collaboration, a consortium of cohort studies that investigate the 
association between subclinical thyroid dysfunction and clinical  outcomes20.
Data extraction and quality assessment. We contacted investigators from all prospective cohort stud-
ies that met the inclusion criteria to collaborate in our IPD analysis by sharing their data. We requested IPD 
on thyroid status at baseline (TSH, fT4), and free triiodothyronine (fT3)), socioeconomic status (education, 
income), demographics (sex, age), medication use (levothyroxine, anti-thyroid, anti-depressant, thyroid-altering 
medication, including lithium, and amiodarone), and on depressive symptoms as measured on a validated con-
tinuous scale at baseline and at any follow-up. Each study was approved by its local ethics committee and all par-
ticipants gave informed consent for the original studies. We used the Newcastle–Ottawa Scale (NOS) to assess 
the quality of the studies  included21. The NOS contains eight items that focus on selection, comparability and 
outcome. The scale is scored from zero to nine stars; the highest score indicates the best methodological quality. 
We classed the studies as good, fair, and poor quality based on their star rating. We also assessed the certainty in 
the evidence with the GRADE tool (www.grade worki nggro up.org). The certainty of evidence based on obser-
vational studies is «low», and may be decreased to «very low» for several reasons including study limitations 
(i.e. study quality), inconsistency, indirectness, imprecision, or increased for other considerations like particular 
design features of extremely rigorous well-conducted observational  studies22. For assessing the study limitations, 
the final NOS score of the studies included in the main analysis was used. E.g. if all the included studies have a 
good NOS quality score the study limitations in the GRADE can be judged as “not serious” (Appendix 4).
Thyroid function testing. Consistent with our previous IPD analyses, we used uniform TSH cut-off levels 
and study-specific fT4 cut-off values to define the thyroid  status20,23,24. We defined euthyroidism as TSH levels 
between 0.45 and 4.50 mIU/L. Subclinical hyperthyroidism was defined as TSH levels < 0.45 mIU/L with nor-
mal fT4 values, and subclinical hypothyroidism as TSH levels > 4.50 and < 20 mIU/L and fT4 values within the 
reference range. For fT4, we used study specific cut-offs because these measurements show greater inter method 
variation than do sensitive 3rd generation TSH  assays20. We excluded participants with fT4 values out of the 
reference range. When fT4 values were missing, we considered participants with TSH levels below 0.45 mIU/L 
to have subclinical rather than overt hyperthyroidism and participants with TSH levels above 0.45 mIU/L and 
below 20 mIU/L to have subclinical rather than overt hypothyroidism, because most adults with a TSH level in 
this range rather have subclinical than overt thyroid  dysfunction25,26. We performed a sensitivity analysis exclud-
ing participants with missing fT4 to verify that the results remained robust, meaning that the effect size was not 
clinically different from the main result. We additionally performed a sensitivity analysis examining the differ-
ence in depressive symptoms between the subclinical hyperthyroidism and euthyroid participants, excluding 
participants with missing fT3 levels or values outside the reference range. We completed two sensitivity analyses 
excluding participants with thyroid medication (levothyroxine or anti-thyroid medication), and with thyroid 
altering medication (anti-thyroid drugs, levothyroxine, amiodarone, lithium) at baseline or follow-up.
Depressive symptoms. Since studies used different continuous scales to measure depressive symptoms, 
we converted scores from different scales to the Beck Depression Inventory (BDI) scale, a commonly used 
depressive symptoms  scale27,28. The BDI scale ranges from 0 to 63, with higher values indicating greater fre-
quency and severity of depressive symptoms; the minimal clinically important difference is 5  points28. We calcu-
lated the conversion factor by dividing the range of the BDI scale by the range of the original scale. For example, 
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to convert the Center for Epidemiological Studies Depression (CESD) scale to the BDI, we used a conversion 
factor of 1.05 (63 (BDI range) ÷ 60 (CESD range))28. To transfer measurements from the CESD scale to the BDI 
scale, we then multiplied each individual’s CESD value by the conversion factor. The primary outcome was 
depressive symptoms measured at first available follow-up, expressed on the BDI scale. As previously defined in 
the study protocol we converted measurements to the BDI scale instead of a standardised scale to facilitate the 
 interpretation18,28. In a sensitivity analysis, we used the original scale to calculate the mean difference in each 
study and then we pooled the standardised mean differences (SMDs) across the studies. We coded SMDs so 
that positive values would indicate more severe depressive symptoms in participants with subclinical thyroid 
dysfunction than in euthyroid controls: < 0.40 was a small effect; 0.40–0.70 was a moderate effect, and > 0.70 was 
a large effect,  respectively29. Since depressive symptoms could be influenced by medications, we conducted a 
sensitivity analysis excluding participants with antidepressant medication at baseline or follow-up. A secondary 
outcome was depressive symptoms at baseline, expressed on the BDI scale. An additional secondary outcome 
was depressive symptoms at the last available follow-up and at the third year of follow-up, expressed on the BDI 
scale. We chose a follow-up at year three because most of the cohorts had this follow-up time in common. Stud-
ies without a 3-year follow up were excluded from this analysis. Another secondary outcome was incidence of 
depressive symptoms at the first available follow-up. For the outcome of incidence of depression, we analysed 
data on diagnosis of depression or established cut-off points for presence of depression from the continuous 
depressive symptoms scales (cut-off points were defined as; (Geriatric Depression Scale 15-item (GDS-15): > 5 
30, CESD-20: > 21 31, CESD-10: ≥ 832, Hospital Anxiety and Depression Scale (HADS): > 1233). In the analysis of 
incidence of depression, we excluded participants with diagnosed depression or with depressive symptoms score 
above the cut-off at baseline. In the primary outcome analyses, we excluded participants with missing data on 
depressive symptoms at baseline or follow-up. In a sensitivity analysis, we did not exclude those participants, 
but used multiple imputation for missing data on depressive symptoms. We additionally conducted a sensitivity 
analysis excluding participants with dementia (Mini-Mental State Examination (MMSE) score < 24, or diagnosis 
of dementia), since the relationship between dementia and depression is  complex34.
Analysis. We performed a two-stage IPD analysis. In the first stage, we estimated the effect size for each study 
separately. For the primary outcome, we calculated the mean difference in BDI score between participants with 
subclinical hypothyroidism or hyperthyroidism and euthyroid controls using a multivariable linear regression 
model adjusted for age, sex, depressive symptoms at baseline, education, and income. We only included studies 
with data on depressive symptoms at baseline because adjusting for depressive symptoms at baseline adjusts for 
imbalance and accounts for the correlation between baseline and follow-up, which makes the effect estimates 
more  precise35. In a sensitivity analysis, we additionally included studies without baseline data on depressive 
symptoms. When comparing incidences of depression, we calculated odds ratio for incidence of depression at 
the first available follow-up between subclinical hypothyroidism or hyperthyroidism and euthyroid controls 
using a multivariable logistic regression model adjusted for age, sex, depressive symptoms at baseline, income, 
and education. For the cross-sectional analysis at baseline, we calculated mean difference in BDI score between 
participants with subclinical hypo- or hyperthyroidism and euthyroid control, adjusted for age, sex, education, 
and income. In the second stage of the IPD analysis, we pooled derived mean differences or odds ratios from all 
the different studies from the first stage using a random effects model.
To identify sub-populations at risk and possible sources of heterogeneity, we conducted predefined subgroup 
and sensitivity analyses on the primary outcome. We performed predefined subgroup analyses by age (younger 
and older than 75 years old), by sex, by TSH levels (4.51–6.99 mIU/L, 7.00–9.99 mIU/L, 10.0–20.0 mIU/L)20, 
and by levothyroxine use at baseline.
We performed a sensitivity analysis excluding the HUNT study as this was the biggest study included in the 
analysis and therefore had the biggest weight for the overall result.
Heterogeneity was estimated with  I2 and the Q test. Statistical significance testing was 2-sided and P < 0.05 
was considered statistically significant. All analyses were conducted with Stata, release 15 (StataCorp).
Ethics approval and consent to participate. Statement on ethical approval from ethics committee This is 
a manuscript that analysed existing cohort data. Each study in the individual participant data set received local 
ethical approval. Our analysis did not include identifiable data.
Statement on guidelines followed The manuscript adheres to the preferred reporting items for systematic 
reviews and meta-analyses (PRISMA) statement for IPD systematic reviews and to the PRISMA statement for 
systematic review protocols.
Statement on written informed consent from the participants This manuscript analysed existing cohort data, 
each study in the individual participant data set received informed consent from the participants. Our analysis 
did not include identifiable data.
Results
Of the 1047 studies we identified through the literature search, four studies met our inclusion criteria (Appendix 
2)11,13,16,36. From within the Thyroid Studies Collaboration we identified seven additional studies where data on 
subclinical thyroid dysfunction and depressive symptoms had not been published. We invited the investigators 
of eligible studies to collaborate in this IPD analysis; only one investigator, from a study identified by the lit-
erature review, declined to  participate16. This study only presented a dichotomised result in the publication, so 
we could not combine this aggregate data with our main IPD analysis. We received IPD from ten studies with 
33,769 participants that met our inclusion criteria. For the primary outcome analysis, we included only studies 
with a continuous outcome, and in which depressive symptoms had been measured at baseline. Six studies met 
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these criteria, including 23,038 participants. Mean age (± SD) was 60 years (± 13), 65% were female, and median 
TSH was 1.63 mIU/L (Table 1). 21,025 (91%) participants were euthyroid, 1342 (6%) participants had subclinical 
hypothyroidism, and, 671 (3%) had subclinical hyperthyroidism. In sensitivity analyses, we additionally included 
the three studies that did not measure depressive symptoms at  baseline37–39. For the secondary outcome of inci-
dence of depression, we additionally included the Health in Men Study, which did not use a continuous scale 
to measure depressive symptoms but assessed incidence of depression via data  linkage36. Depressive symptoms 
scores at baseline were balanced between groups in each cohort and on average the correlation between depres-
sive symptoms at baseline and follow-up was 0.6 across studies (Appendix 6).
Quality assessment. Based on the NOS, the quality of all studies that we included in the primary outcome 
analysis was good (Appendix 3). Certainty in the evidence assessed with the GRADE tool for the primary out-
come was low (Appendix 4). Because of the low number of studies, we did not assess publication  bias40.
Subclinical hypothyroidism. At first available follow-up (mean 8.2 (± 4.3) years), there was no difference 
in the primary outcome of BDI score between subclinical hypothyroidism and euthyroid controls (pooled mean 
difference (MD) 0.29, 95% CI − 0.17 to 0.76) with a low heterogeneity  (I2 = 15.6%) (Fig. 1).
Secondary outcomes are shown in Fig. 2. At baseline there was neither relevant difference in depressive 
symptoms between euthyroid participants (mean BDI = 10.28) and participants with subclinical hypothyroid-
ism (mean BDI = 9.63), nor in multivariable analysis adjusted for age, sex, education, and income (MD in BDI 
Table 1.  Study characteristics and baseline data. Leiden 85 + Study13 Leiden 85 plus Study; PROSPER11 
prospective study of Pravastatin in the elderly at risk; Health ABC Study46 The health, aging and body 
composition study; CHS32 cardiovascular health study; InChianti Study47 Invecchiare in Chianti Study; HUNT48 
Nord-Trøndelag Health Study; PREVEND49 prevention of renal and vascular end-stage disease; MrOS50 
osteoporotic fractures in men study; SHIP51 study of health in pomerania, HIMS36 health in men study; y year; 
GDS-15 geriatric depression scale 15-item; CESD-10/-20 center for epidemiologic studies depression 10/20-
item scale; HADS hospital anxiety and depression scale; BDI beck depression inventory scale; TSH thyroid 
stimulating hormone; FT4 free thyroxine; N.A., not available; No. number. *Not included in the main analysis 
because no data on depressive symptoms at baseline available. † Not included in the main analysis because no 
continuous scale used to measure depressive symptoms during follow up. Incidence of depression available (via 
Data Linkage). ‡ No validated depression scale used. § SHIP includes participants from Pomerania, where an 
iodine supplementation program began in the mid-1990s. This shifted the distribution of TSH values towards 
the left in its first years, which lowered TSH values in the population of the SHIP Study during baseline 
examinations in 1997–2001. ¶ follow-up via data-linkage from baseline 2001–2004, censor date 2013. **In the 
sensitivity analyses and subgroup analyses we only assessed the effect estimate at the first available follow-up.
Study, Place
No. of 
Participants
Age, mean 
(range), y
Women, No. 
(%)
Original 
depression 
scale, (range)
Dementia, 
No. (%)
Thyroid 
medication, 
No. (%)
Depression 
medication, 
no. (%)
Median TSH, 
mIU/l
Normal range 
FT4, pmol/l
First/last 
available 
follow-up 
(mean), y
Studies included in the main analyses
Leiden 
85 + Study, The 
Netherlands
281 85 (85–85) 185 (66) GDS-15 (0–15) 37 (13) 11 (4) 8 (3) 1.57 13–23 1.0/3.7
PROSPER 
Study, The 
Netherlands
405 75 (70–83) 190 (47) GDS-15 (0–15) 0 (0) 10 (2) 12 (3) 2.04 12–18 3.0/3.0
InChianti 
Study, Italy 952 66 (21–98) 515 (54)
CESD-20 
(0–60) N.A 24 (2) 29 (3) 1.34 10–27 3.3/3.6
Health ABC 
Study, United 
States
2250 75 (69–81) 1139 (51) CESD-20 (0–60) 481 (21) 212 (9) 7 (< 1) 2.15 10–23 2.9/7.8
CHS, United 
States 3419 75 (64–98) 2013 (59)
CESD-10 
(0–30) 451 (13) 280 (8) 57 (2) 2.14 9–22 1.1/8.2
HUNT, 
Norway 15,731 53 (19–86) 10,963 (70) HADS (0–21) N.A 684 (4) N.A 1.50 8–20 11.2/11.2
Overall 23,038 60 (19–98) 15,005 (65) N.A 969 (4) 1221 (5) 113 (< 1) 1.63 N.A 8.2/9.9
Studies only included in sensitivity analyses or secondary outcomes
MrOs*, United 
States 1356 73 (65–92) 0 (0)
GDS-15 
(0–15) 29 (2) 93 (7) 71 (5) 2.04 9–24 3.9/**
PREVEND*, 
The Nether-
lands
2124 48 (28–75) 1086 (51) N.A.‡ N.A 36 (2) N.A 1.37 12–22 4.2/**
SHIP*, Ger-
many 2139 46 (20–80) 1133 (53) BDI (0–63) 46 (12) 105 (5) 31 (1) 0.68
§ 8–19 9.5/**
HIMS†, Aus-
tralia 4032 77 (71–89) 0 (0) N.A 212 (5) 126 (3) 261 (7) 2.00 10–23 N.A
¶
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scores − 0.05 95% CI =  − 0.50–0.39  I2 = 0.0%). In the five cohorts (N = 6393) with data on depressive symptoms at 
3 years follow-up, BDI scores did not differ between participants with subclinical hypothyroidism and euthyroid 
controls (MD 0.36, 95% CI − 0.18–0.90,  I2 = 0.0%). At last available follow-up (9.9 ± 3.3 years) there was no asso-
ciation in BDI score between subclinical hypothyroidism and euthyroid control (MD 0.05, 95% CI − 0.38–0.48, 
1342
Study
Leiden 85+
PROSPER
Health ABC
CHS
InChianti
HUNT
Summary
No. of Participants
Euthyroid
237
345
1910
2852
866
14815
21025
SHypo
26
44
272
466
25
509
MD in BDI (95% CI)
2.87 (−0.28, 6.02)
0.00  (−1.91, 1.92)
0.60 (−0.13, 1.33)
0.50 (−0.29, 1.30)
−0.52 (−3.36, 2.31)
-0.17 (−0.81, 0.47)
0.29 (−0.17, 0.76)
Weight %
2.12
5.56
29.07
25.67
2.61
34.96
100.00
Overall I² = 15.6 %, tau² = 0.05, Q = 5.93
Higher Depression Score 
in Euthyroid
Higher Depression 
Score in  SHypo
-4 -3 -2 -1 0 1 2 3 4 5 6
a) Difference in BDI score between participants with subclinical hypothyroidism and euthyroid participants after the first 
available follow up*
Overall I² = 3.2 %, tau² = 0·02, Q = 5.16 
Study
Leiden 85+
PROSPER
Health ABC
CHS
InChianti
HUNT
Summary
Euthyroid
237
345
1910
2852
866
14815
21025
SHyper
18
16
68
101
61
407
671
MD in BDI (95% CI)
3.53 (−0.28, 7.34)
0.27 (−2.79, 3.32)
-0.20 (−1.58, 1.18)
-0.91 (−2.50, 0.68)
0.61 (−1.24, 2.47)
-0.17 (-0.89, 0.54)
-0.10 (−0.67, 0.48)
Weight %
2.26
3.50
16.54
12.62
9.39
55.70
100.00
Higher Depression Score 
in Euthyroid
Higher Depression 
Score in  SHyper
No. of Participants
b) Difference in BDI score between participants with subclinical hyperthyroidism and euthyroid participants after the 
first available follow up*
-4 -3 -2 -1 0 1 2 3 4 5 6
Figure 1.  (a) Difference in BDI score between participants with subclinical hypothyroidism and euthyroid 
participants after the first available follow up*. (b) Difference in BDI score between participants with subclinical 
hyperthyroidism and euthyroid participants after the first available follow up*. * Analysis adjusted for depressive 
symptoms at baseline, sex, age, and education (The CHS, Health ABC Study, and the InChianti Study were 
additionally adjusted for income). Overall mean BDI score at first follow-up was 10.67 with a standard deviation 
of 8.99. Abbreviations: SHypo Subclinical Hypothyroidism; SHyper Subclinical Hyperthyroidism; Leiden 85+ (9) 
Leiden 85 plus Study; PROSPER (7)  Prospective Study of Pravastatin in the Elderly at risk; Health ABC Study 
(40) The Health, Ageing and Body Composition Study; CHS (26) Cardiovascular Health Study; InChianti Study 
(41) Invecchiare in Chianti Study; HUNT (42) Nord-Trøndelag Health Study; BDI Beck Depression Inventory 
Score (range 0–63, minimal clinically important difference 5 points); MD Mean Difference; CI Confidence 
Interval, No. Number.
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 I2 = 0.0%). The odds ratio for incident depression comparing subclinical hypothyroid and euthyroid participants 
was 1.24 (95% CI 0.73–2.09,  I2 = 56.4%).
Results of sensitivity analyses in which we excluded participants taking thyroid medication (N = 21,391), 
thyroid altering medication (N = 21,384) or antidepressant medication (N = 23,175), participants with dementia 
(N = 22,224), or participants without fT4 measurements at baseline (N = 5618), or in which we excluded the 
study with the biggest weight (HUNT) (N = 7043), were similar comparable to those from our primary analysis 
(Table 2). When we used multiple imputation, depressive symptoms between subclinical hypothyroidism and 
euthyroidism did also not differ in a sensitivity analysis that included participants with t4 data on outcome and 
depressive symptoms at baseline (N = 45,398). Results of a sensitivity analysis in which we included studies 
without baseline information on depressive symptoms (N = 27,361) were similar to those of the main analysis. 
In a sensitivity analysis that used the original scale from each study, we found SMD between groups of 0.04 
(95% CI =  − 0.02–0.09). Figure 3 shows the results of several subgroup analyses. After stratifying the population 
that was included in the primary outcome analysis by age (participants older and younger than 75), by sex, by 
levothyroxine treatment at baseline, and by different TSH levels, we found no significant differences in depres-
sive symptoms scores.
Subclinical Hyperthyroidism. There was no difference in the primary outcome of depressive symptoms 
between subclinical hyperthyroidism and euthyroid controls (MD 0.10, 95% CI − 0.67–0.48,  I2 = 3.2%) at first 
available follow-up (Fig. 1), as well as at year three follow-up, and at last available follow-up (Appendix 5a). At 
baseline, there was no difference in depressive symptoms expressed on the BDI scale between euthyroid par-
ticipants (Mean BDI = 10.26) and participants with subclinical hyperthyroidism (Mean BDI = 10.28) (Appendix 
5). Odds for incidence of depression were not higher for participants with subclinical hyperthyroidism than 
Secondary Outcomes
At 3 years follow−up
At last available follow-up
Incidence of depression
SHypo
748
1342
1592
Euthyroid
5645
21025
24098
Effect Size
MD in BDI Score (95% CI)
0.36 (−0.18 to 0.90)
0.05 (−0.38 to 0.48)
Odds Ratio (95% CI)
1.24 (0.73 to 2.09)
More depressive 
symptoms / depression 
in Euthyroid
More depressive 
symptoms / depression 
in SHypoNo. of participants
-0.5 0.5 1 1.5
0.25 1 4
At baseline -0.05 (−0.50 to 0.39)134221025
Secondary outcomes - Association between subclinical hypothyroidism and depressive symptoms*
0
Figure 2.  Secondary outcomes—association between subclinical hypothyroidism and depressive symptoms*. 
* Analysis adjusted for depressive symptoms at baseline, sex, age, and education (The CHS, Health ABC Study, 
and the InChianti Study were additionally adjusted for income). † Analysis includes the same studies as for the 
primary outcome analysis: Leiden 85+ (9), PROSPER (7), Health ABC Study (40), CHS (26), InChianti Study 
(41), HUNT (42). ‡ Analysis includes the same studies as in the primary outcome analysis except of HUNT (42). 
§ Analysis includes the same studies as in the primary outcome analysis plus the HIMS (30) which only had data 
on incidence of depression and no continuous measurement. Abbreviations: SHypo Subclinical Hypothyroidism; 
MD Mean Difference; BDI Score Beck Depression Inventory Score (range 0–63, minimal clinically important 
difference 5 points); CI Confidence Interval; No. Number.
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for euthyroid controls (Appendix 5a). Our results remained robust in several sensitivity and subgroup analyses 
(Appendix 1b,c).
Discussion
In this IPD analysis of 23,038 participants from six prospective cohort studies, we found no clinically relevant dif-
ferences in depressive symptoms during follow-up between subclinical hypothyroidism or hyperthyroidism and 
euthyroid controls. Depressive symptoms of participants with subclinical hypothyroidism or hyperthyroidism 
were not different from symptoms of euthyroid control participants at baseline or at any follow-up. Participants 
with subclinical hypothyroidism were not at increased risk for incidence of depression. Our results were robust 
across all sensitivity analyses.
To our knowledge, no pooled IPD analysis has previously assessed the association of subclinical thyroid dys-
function and depressive symptoms. The results are in contrast with two previous meta-analyses of cross-sectional 
 studies7, 8 which found a positive association between subclinical hypothyroidism and depression. Reasons for 
difference in results could be that we included published and unpublished studies, that we did not include stud-
ies only on depressed patients, that we did not include case–control studies and cross-sectional studies (only 
cross-sectional analysis of prospective studies in our analysis, as they are considered of higher validity), and that 
we analyzed individual participant data, which leads to far more reliable  results17,35. With individual participant 
data, we could use standardized definition of subclinical hypo- and hyperthyroidism for all studies, which was 
not possible in these study-level meta-analyses. Our results are in line with the results found by the Kangbuk 
Samsung Health Study showing that participants with subclinical hypothyroidism had no higher incidence of 
depression than euthyroid  controls16.
Our study has some limitations. First, younger people were underrepresented because three of six studies 
included participants only over 64. However, our sensitivity analysis that excluded participants over 75 also 
yielded no association, but we were able to include too few participants to assess risk among middle-aged adults. 
Second, we were limited by measurement of depressive symptoms using different scales across studies, so that we 
Table 2.  Sensitivity analyses on subclinical hypothyroidism and depressive symptoms at first available 
follow-up* SHypo subclinical hypothyroidism; TSH thyroid-stimulating hormone; FT4 free thyroxine; MD 
mean difference; SMD standardised mean difference; BDI Score Beck DEPRESSION INVENTORY SCORE 
(range 0–63, minimal clinically important difference 5 points); CI confidence Interval; No number. *Analyses 
adjusted for depressive symptoms at baseline (In sensitivity analysis 7: except studies without measurement), 
sex, age, income, and education (The CHS, Health ABC Study, and the InChianti Study were additionally 
adjusted for income). † The main analysis includes the same studies as for the primary outcome analysis: Leiden 
85 + 13,  PROSPER11, Health ABC  Study46,  CHS32, InChianti  Study47,  HUNT48. Sensitivity analyses 1–4, 6, 
8, 10: the same studies as in the main analysis were included, only participants with a certain measurement 
missing were excluded. Sensitivity analysis 5: the same studies as in the main analysis without the Health ABC 
Study 32 because in this study FT4 was not measured in the euthyroid group. Sensitivity analysis 7: the same 
studies as in the main analysis plus 3 studies that did not have data for depressive symptoms at baseline were 
included (PREVEND (Prevention of Renal and Vascular end-stage Disease)49, MrOS (Osteoporotic Fractures 
in Men)50, SHIP (Study of Health in Pomerania)51). Sensitivity analysis 9: the same studies as in the main 
analysis without the  HUNT48 study as the HUNT study has the biggest weight in the summarized result of the 
main outcome (34.96%). ‡ Mean differences using the original scale for depressive symptoms within each study 
were pooled. § Overall mean BDI score at first follow-up of all 23,038 participants was 10.67 with a standard 
deviation of 8.97.
Sensitivity analysis
No. of participants
No. of included  studies† MD in BDI score (95% CI),  I2Euthyroid SHypo
Main analysis 21,025 1342 6 0.29 (− 0.17–0.76) §, 15.6%
1) Excluding participants with thyroid 
medication 20,268 1123 6 0.30 (− 0.15–0.75), 4.7%
2) Excluding participants with thyroid 
altering medication 20,261 1123 6 0.30 (− 0.15–0.76), 4.8%
3) Excluding participants with antide-
pressant medication 20,897 1327 6 0.32 (− 0.19–0.83), 26.1%
4) Excluding participants with dementia 20,203 1222 6 0.24 (− 0.17–0.65), 0.0%
5) Excluding participants without FT4 
measurement 4550 1068 5 0.17 (− 0.49–0.83), 11.8%
6) Using multiple imputation to impute 
missing outcome data 42,759 2639 6 0.35 (− 0.10–0.81), 10.7%
7) Including studies without depressive 
symptoms at baseline 25,851 1510 9 0.25 (− 0.13–0.63), 0.0%
8) Not adjusted for income 21,509 1413 6 0.22 (− 0.22, 0.65), 11.1%
9) Excluding HUNT 6210 833 5 0.54 (0.04, 1.05), 0.0%
SMD in depressive symptoms (95% CI),  I2
10) Using original scale for depressive 
 symptoms‡ 21,025 1342 6 0.04 (− 0.02–0.09), 27.2%
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were unable to combine the effect estimates from different studies using their original scales. To standardise the 
scale between studies, we converted scores from the various scales to the BDI scale, a common scale whose scores 
are easy to  interpret28. As there was no validated conversion factor, we examined whether our results remained 
robust when we converted the original scores to a standardised scale, which yielded similar findings. Third, we 
did not have access to information about treatment prior to baseline; patients with subclinical thyroid dysfunction 
and depressive symptoms may have been more frequently diagnosed with subclinical thyroid dysfunction and 
been treated to restore euthyroidism prior to baseline, in which case the subclinical thyroid dysfunction group 
at baseline would overrepresent the number of people who did not develop depressive symptoms. Fourth, the 
diagnosis of subclinical hypothyroidism was based on one assessment of TSH, and did not depend on a second 
Outcome by Subgroup
Main Outcome
Age, y
≥ 75
<75
Sex
Female
Male
Levothyroxine at BL
Yes
No
SHypo split in different TSH
levels
4.51 − 6.99 mIU/L
7.00 − 9.99 mIU/L
10.00 – 20 .00 mIU/L
No. of Participants
Euthyroid
21025
2987
18038
13557
7468
576
17505
21025
21025
21025
SHypo
1342
432
910
923
419
142
732
917
268
157
MD in BDI 
Score(95% CI)
0.29 (−0.17, 0.76)
0.07 (−0.63, 0.78)
0.37 (-0.25, 1.00)
0.35 (−0.35, 1.04)
0.08 (−1.09, 1.25)
0.03 (−1.34, 1.29)
0.20 (−0·30, 0.70 )
0.26 (−0.27, 0.80)
0.55 (−0.68, 1.78)
0.17 (−0.94, 1.27)
−1 0 1 2 3                4                 5
Higher Depression Score 
in Euthyroid
Higher Depression 
Score in  SHypo
 The association between subclinical hypothyroidism and depressive symptoms by subgroups* 
−2
Figure 3.  The association between subclinical hypothyroidism and depressive symptoms by subgroups*. 
* Analysis adjusted for depressive symptoms at baseline, sex, age, and education (The CHS, Health ABC 
Study, and the InChianti Study were additionally adjusted for income). Abbreviations: SHypo Subclinical 
Hypothyroidism; TSH Thyroid-Stimulating Hormone; MD Mean Difference; BDI Score Beck Depression 
Inventory Score (range 0–63, minimal clinically important difference 5 points); CI Confidence Interval; No. 
Number.
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verified measurement, which is a limitation of most published large cohorts that have examined the risk of sub-
clinical thyroid  dysfunction20,41. Based on a single elevated or decreased TSH level, participants might revert to 
normal thyroid function over follow-up, which could have biased the results towards the null. However, previous 
IPD analyses including cohorts with just one TSH assessment documented an association between subclini-
cal thyroid dysfunction and both coronary heart disease or  fractures20,24. Inferring a causal relationship from 
observational data is challenging and, for this reason, we completed a series of sensitivity analysis to minimise 
the potential effects of residual confounding and bias.
Our study was strengthened by its IPD analysis, considered the most appropriate method in evidence syn-
thesis since it offers many advantages over aggregate data  analysis42. For example, our results do not suffer from 
the ecological bias of study-level meta-analyses. We could also standardise definitions of predictors and out-
comes, use uniform adjustments for potential confounders to reduce heterogeneity across studies, and include 
unpublished data to increase the robustness of our results and our power to detect associations. Because our 
IPD analysis was large, we could assess the effects of age, sex, thyroid medication, antidepressant medication, 
and TSH levels in subgroup analyses.
Current guidelines for the management of people with subclinical hypothyroidism tend to recommend thy-
roid hormone substitution for adults with TSH levels > 10 mIU/L and for people with lower TSH values who are 
young or symptomatic, although some recent guidelines have more narrow  indications43,44. As we found no asso-
ciation between subclinical hypothyroidism and depressive symptoms, one might infer that thyroid hormones 
would be of limited benefit for the treatment of depressive symptoms in affected people with subclinical hypo-
thyroidism. This is in line with a previous meta-analysis of four small randomised clinical trials (total N = 278) 
that found no positive association between thyroid hormone therapy and depressive  symptoms45. Overall, our 
results do not support increased risk of depressive symptoms in adults with subclinical thyroid dysfunction.
Data availability
The datasets analysed during this study are available from the corresponding author on reasonable request.
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